阿利沙坦酯联合前列地尔对糖尿病伴微量白蛋白尿的干预分析  

Intervention Analysis of Allisartan Lsoproxil Combined with Alprostadil in Diabetic Patients with Microalbuminuria

作　　者：王芳 刘德慧[1] 吴乙偲 曾芳 WANG Fang;LIU Dehui;WU Yicai;ZENG Fang(Ganzhou People's Hospital,Ganzhou Jiangxi 341000,China)

机构地区：[1]赣州市人民医院,江西赣州341000

出　　处：《药品评价》2023年第2期214-216,共3页Drug Evaluation

基　　金：赣州市指导性科技计划项目(GZ2019ZSF147)。

摘　　要：目的 观察阿利沙坦酯联合前列地尔治疗糖尿病伴微量白蛋白尿(MAU)的效果。方法 选取2020年2月至2022年7月赣州市人民医院收治的80例确诊为2型糖尿病伴MAU的患者,且均伴高血压,采用随机数字表法分为A组、B组,各40例。在常规治疗基础上,A组用阿利沙坦酯治疗,B组经阿利沙坦酯联合前列地尔治疗,治疗2周。于治疗前、治疗2周,比较两组尿微量白蛋白(mAlb),估算的肾小球滤过率(eGFR),血压水平,炎性因子高敏C反应蛋白(hs-CRP)以及血凝变化[凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)]。结果 治疗2周,两组m Alb、eGFR显著下降,且B组低于A组,差异有统计学意义(P<0.05);两组血压显著下降,但两组间比较差异无统计学意义(P>0.05);两组hs-CRP水平显著下降,且B组低于A组,差异有统计学意义(P<0.05)。治疗前、后,两组APTT、PT比较,差异无统计学意义(P>0.05)。结论 阿利沙坦酯联合前列地尔应用于糖尿病伴MAU患者中,可降低血清hs-CRP、mAlb、eGFR水平,且对凝血功能无影响。Objective To observe the intervention value of allisartan lsoproxil combined with alprostadil in diabetes mellitus with microalbuminuria(MAU).Method Eighty patients diagnosed with type 2 diabetes mellitus with MAU and hypertension admitted to Ganzhou People's Hospital from February 2020 to July 2022 were selected and divided into group A and group B by random number table,with 40 cases each.Based on conventional treatment,group A was treated with allisartan lsoproxil alone,and group B was treated with allisartan lsoproxil combined with alprostadil for 2 weeks.Urinary microalbumin(mAlb),estimated glomerular filtration rate(eGFR),blood pressure levels,inflammatory high-sensitivity C-reactive protein(hs-CRP),and hemagglutination changes(PT,APTT)were compared between the two groups before and after 2 weeks of treatment.Results After 2 weeks of treatment,mAlb and eGFR in 2 groups were significantly decreased,and group B was lower than group A,with statistical difference(P<0.05);blood pressure decreased significantly in both groups,but there was no significant difference in the ratio between the two groups(P>0.05);hs-CRP level was significantly decreased between the two groups,and group B was lower than group A,with statistical difference(P<0.05).There were no significant differences in APTT and PT between the two groups before and after treatment(P>0.05).Conclusions Allisartan lsoproxil combined with alprostadil can reduce serum hs-CRP level and then mAlb and eGFR level in diabetic patients with MAU,and has no effect on coagulation function.

关 键 词：糖尿病肾病 白蛋白尿 阿利沙坦酯 前列地尔 尿微量白蛋白 

分 类 号：R587.2[医药卫生—内分泌] R696.2[医药卫生—内科学]